Physician profile
Gregory E Stampfli
NPI 1174637359
$1,918.07
in general payments reported to CMS, 2019-2025
26 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $355 · 2021: $182 · 2022: $143 · 2023: $132 · 2024: $450 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.22 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $337.06 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $203.21 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.03 | 2019-2024 | Jardiance |
| Pfizer INC. | $158.97 | 2019-2025 | |
| Lilly USA, LLC | $139.83 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $117.51 | 2019-2021 | |
| Boston Scientific Corporation | $117.31 | 2024-2025 | Watchman |
| Novo Nordisk INC | $114.40 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $100.52 | 2019-2025 | Repatha, Evenity, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.10 | 2023-2025 | Caplyta |
| Allergan, INC. | $58.19 | 2020 | |
| Phadia US INC. | $50.48 | 2024-2025 | Immunocap |
| Exact Sciences Corporation | $33.36 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $30.39 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $25.74 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.22 | 2025 | |
| Dexcom, INC. | $24.02 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $20.33 | 2019 | |
| Alkermes, INC. | $19.34 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $18.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.35 | 2024 | |
| Inspire Medical Systems, INC. | $15.28 | 2024 | Inspire |
| Daiichi Sankyo INC. | $13.68 | 2024 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2019 | |
| Viiv Healthcare Company | $12.32 | 2020 | |
| Abbvie INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stampfli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.